Suppr超能文献

表达印度HIV-1C基因的基于Semliki森林病毒的自扩增RNA在小鼠中的免疫原性。

Immunogenicity of Semliki Forest virus based self-amplifying RNA expressing Indian HIV-1C genes in mice.

作者信息

Ajbani Seema P, Velhal Shilpa M, Kadam Ravindra B, Patel Vainav V, Bandivdekar Atmaram H

机构信息

Department of Biochemistry and Virology, National Institute for Research in Reproductive Health, Indian Council of Medical Research, J. M. Street, Parel, Mumbai 400012, India.

出版信息

Int J Biol Macromol. 2015 Nov;81:794-802. doi: 10.1016/j.ijbiomac.2015.09.010. Epub 2015 Sep 8.

Abstract

Development of recombinant vaccines is considered as a promising approach to prevent transmission and eradication of HIV/AIDS. Candidate vaccines tested so far have shown poor to modest efficacy. Self-amplifying RNAs of positive strand alphaviruses are reported to be promising vectors for development of recombinant vaccines. This study describes the construction, in vitro expression and in vivo immunogenicity of recombinant RNA vaccines developed by individually cloning gag, env and polRT genes of primary HIV-1C Indian isolates using Semliki Forest virus (SFV) vector. HIV-1C specific T cell responses were detected in mice immunized with rSFV2gen/gag RNA by IFN-γ ELISPOT assay. Furthermore, using flow cytometry based intracellular cytokine staining (ICCS) assay HIV-1C specific IL-2 responses were detected in immunized mice that were mediated by both CD4(+) and CD8(+) T cells. Mice immunized with rSFV2gen/env RNA elicited HIV-1C Env-specific antibodies as detected by gp120 ELISA. The Env, Gag and Pol (RT) RNA constructs in combination elicited better HIV-1C Env-specific humoral responses compared to mice immunized with Env RNA alone. In conclusion, rSFV2gen RNA constructs encoding HIV-1C antigens elicited clear cell mediated and humoral immune responses in mice, thus demonstrating the potential of self-amplifying rSFV2gen RNA as a promising candidate for anti-HIV vaccine development.

摘要

重组疫苗的研发被认为是预防艾滋病毒/艾滋病传播和根除的一种有前景的方法。迄今为止测试的候选疫苗显示出的疗效从较差到一般。据报道,正链甲病毒的自我扩增RNA是开发重组疫苗的有前景的载体。本研究描述了通过使用塞姆利基森林病毒(SFV)载体分别克隆原发性HIV-1C印度分离株的gag、env和polRT基因而开发的重组RNA疫苗的构建、体外表达和体内免疫原性。通过IFN-γ ELISPOT试验在接受rSFV2gen/gag RNA免疫的小鼠中检测到HIV-1C特异性T细胞反应。此外,使用基于流式细胞术的细胞内细胞因子染色(ICCS)试验,在免疫小鼠中检测到由CD4(+)和CD8(+) T细胞介导的HIV-1C特异性IL-2反应。用rSFV2gen/env RNA免疫的小鼠通过gp120 ELISA检测出产生了HIV-1C Env特异性抗体。与单独用Env RNA免疫的小鼠相比,Env、Gag和Pol(RT)RNA构建体联合使用引发了更好的HIV-1C Env特异性体液反应。总之,编码HIV-1C抗原的rSFV2gen RNA构建体在小鼠中引发了明显的细胞介导和体液免疫反应,从而证明了自我扩增的rSFV2gen RNA作为抗HIV疫苗开发的有前景候选物的潜力。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验